Navigation Links
Influenza study: Meet virus' new enemy

Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.

Working on the premise that too much of a good thing can be a killer, the scientists have advanced previous researchers' methods of manipulating an enzyme that is key to how influenza replicates and spreads.

Their new compounds will lead to a new generation of anti-influenza drugs that the virus' strains can't adapt to, and resist, as easily as they do Tamiful. It's an anti-influenza drug that is becoming less effective against the constantly mutating flu virus.

These increasingly less adequate anti-influenza drugs are currently doctors' best weapons against influenza. They helped the world beat H1N1, swine flu, into submission four years ago.

The journal Science Express has just published online the scientists' study, revealing how to use their newly discovered compounds to interrupt the enzyme neuraminidase's facilitation of influenza's spread.

Tamiful and another anti-influenza drug, Relenza, focus on interrupting neuraminidase's ability to help influenza detach from an infected cell's surface by digesting sialic acid, a sugar on the surface of the cell. The flu virus uses the same sugar to stick to the cell while invading it. Once attached, influenza can invade the cell and replicate. v

This is where the newly discovered compounds come to the still-healthy cells' rescue. They clog up neuraminidase, stopping the enzyme from dissolving the sialic acid, which prevents the virus from escaping the infected cell and spreading.

The new compounds are also more effective because they're water-soluble. "They reach the patient's throat where the flu virus is replicating after being taken orally," says Niikura, a Faculty of Health Sciences associate professor.

"Influenza develops resistance to Replenza less frequently, but it's not the drug of choice like Tamiful because it's not water-soluble and has to be taken as a nasal spray.

"Our new compounds are structurally more similar to sialic acid than Tamiful. We expect this closer match will make it much more difficult for influenza to adapt to new drugs."

Ultimately, the new compounds will buy scientists more time to develop new vaccines for emerging strains of influenza that are resistant to existing vaccines.


Contact: Carol Thorbes
Simon Fraser University

Related biology news :

1. Target for potent first-strike influenza drugs identified
2. Climate change could increase levels of avian influenza in wild birds
3. Harnessing anticancer drugs for the future fight against influenza
4. Influenza research: Can dynamic mapping reveal clues about seasonality?
5. Pandemic controversies: The global response to pandemic influenza must change
6. BYU study: Using a gun in bear encounters doesnt make you safer
7. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
8. Study: Exercise can lead to female orgasm, sexual pleasure
9. U of I study: Lose body weight before gaining baby weight
10. Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis
11. USF study: Common fungicide wreaks havoc on freshwater ecosystems
Post Your Comments:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology: